Champlain Investment Partners LLC Decreases Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Champlain Investment Partners LLC lessened its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 6.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,379,863 shares of the medical device company’s stock after selling 89,298 shares during the quarter. Champlain Investment Partners LLC’s holdings in Tandem Diabetes Care were worth $49,703,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Stifel Financial Corp lifted its position in shares of Tandem Diabetes Care by 6.8% in the third quarter. Stifel Financial Corp now owns 34,072 shares of the medical device company’s stock valued at $1,445,000 after acquiring an additional 2,160 shares in the last quarter. Geode Capital Management LLC raised its stake in Tandem Diabetes Care by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,525,816 shares of the medical device company’s stock valued at $64,722,000 after purchasing an additional 18,187 shares during the last quarter. McIlrath & Eck LLC purchased a new position in Tandem Diabetes Care in the 3rd quarter valued at $52,000. Franklin Resources Inc. boosted its stake in Tandem Diabetes Care by 95.6% during the 3rd quarter. Franklin Resources Inc. now owns 26,785 shares of the medical device company’s stock worth $1,136,000 after purchasing an additional 13,088 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Tandem Diabetes Care by 134.6% in the third quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company’s stock valued at $8,379,000 after buying an additional 113,355 shares during the last quarter.

Insider Buying and Selling at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction on Friday, March 7th. The shares were bought at an average price of $18.12 per share, with a total value of $190,948.56. Following the transaction, the chief operating officer now directly owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Tandem Diabetes Care Stock Down 2.3 %

Tandem Diabetes Care stock opened at $16.86 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company has a market capitalization of $1.12 billion, a PE ratio of -8.74 and a beta of 1.52. The firm has a 50 day moving average price of $22.10 and a 200 day moving average price of $30.28. Tandem Diabetes Care, Inc. has a fifty-two week low of $15.75 and a fifty-two week high of $53.69.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TNDM. Canaccord Genuity Group restated a “buy” rating and set a $63.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. The Goldman Sachs Group dropped their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Mizuho began coverage on Tandem Diabetes Care in a research report on Thursday, April 10th. They set a “neutral” rating and a $20.00 price objective on the stock. Robert W. Baird dropped their target price on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a report on Thursday, February 27th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.88.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.